Skip to main content
. Author manuscript; available in PMC: 2022 Feb 18.
Published in final edited form as: Mol Cancer Ther. 2020 May 19;19(8):1708–1718. doi: 10.1158/1535-7163.MCT-20-0015

Figure 1. Enzalutamide/abiraterone resistant prostate cancer cells are cross-resistant to apalutamide and darolutamide.

Figure 1.

A. C4-2B parental, C4-2B AbiR, C4-2B MDVR and CWR22Rv1 cells were treated with different concentrations of enzalutamide, apalutamide or darolutamide for 3 days. Total cell numbers were counted and cell survival rate was calculated. B. C4-2B parental, C4-2B MDVR, C4-2B AbiR and CWR22Rv1 cells were treated with 20 μM enzalutamide, 20μM apalutamide or 5 μM darolutamide for 0, 3 and 5 days and total cell numbers were determined. C. The clonogenic ability of C4-2B parental, C4-2B MDVR, C4-2B AbiR and CWR22Rv1 cells treated with 20 μM enzalutamide, 20 μM apalutamide or 5 μM darolutamide was analyzed. Enza: enzalutamide, APAL: apalutamide, Abi: abiraterone acetate, DARO: darolutamide. * p<0.05.